Fc gamma R interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model

Sow, H.S.; Benonisson, H.; Breukel, C.; Visser, R.; Verhagen, O.J.H.M.; Bentlage, A.E.H.; ... ; Verbeek, J.S. (2019)

Article / Letter to editor

• Fc gamma R
• anti-PD-L1 mAb therapy
• tumor microenvironment

• All authors: Sow, H.S.; Benonisson, H.; Breukel, C.; Visser, R.; Verhagen, O.J.H.M.; Bentlage, A.E.H.; Brouwers, C.; Claassens, J.W.C.; Linssen, M.M.; Camps, M.; Hall, T. van; Ossendorp, F.; Fransen, M.F.; Vidarsson, G.; Verbeek, J.S.
• Date: 2019-01-15
• Journal: International Journal of Cancer
• Volume: 144
• Issue: 2
• Pages: 345 - 354
• DOI: doi:10.1002/ijc.31899